Search

Melanoma is a malignant tumor of the melanocytes with an unfavorable clinical behavior. Nivolumab, a representative anti‐programmed death 1 (PD‐1) antibody, has recently been used for the treatment of metastatic malignant melanoma. However, there have been few appropriate biomarkers predicting the effect of nivolumab before the administration. Furthermore, the detailed characteristics of peripheral blood mononuclear cell (PBMC) profiles during nivolumab treatment remains unclear. In this study, we investigated fluctuations of PBMC profile during nivolumab treatment. PBMC analysis showed T‐helper (Th)2‐dominant conditions after a first course of nivolumab treatment. In a favorable case treated with nivolumab, a Th1/T‐cytotoxic 1 shift was observed after nivolumab was administrated. These results suggest that flow cytometric analysis of PBMC may be helpful for the treatment of nivolumab. [ABSTRACT FROM AUTHOR]

Ipragliflozin is a new drug for the treatment of diabetes mellitus. Its action of sodium-glucose cotransporter 2 ( SGLT2) inhibition induces glucosuria and decreases blood glucose levels. We report the first case of ipragliflozin-related eczematous drug eruption and a review of the past literature on drug eruptions caused by SGLT2 inhibitors. [ABSTRACT FROM AUTHOR]

Abstract: Enzalutamide is an androgen receptor inhibitor. We report a new cutaneous eruption to this drug and review cases of drug eruptions caused by androgen receptor inhibitors. [ABSTRACT FROM AUTHOR]

The rapid aging of the population has led to an increase in the number of cutaneous squamous cell carcinoma (cSCC) cases among the older population. However, the characteristics of these cases remain unclear. In this study, we aimed to identify the problem by analyzing the clinical characteristics of patients with cSCC aged 90 years and over. In this retrospective study, we analyzed the characteristics of patients aged >90 years with regard to gender, risk factors for cSCC, and disease course, using data from 316 patients with cSCC who underwent surgery at the Kagoshima Medical Centre between October 2014 and September 2022. Patients were separated into two groups based on age: those aged ≥90 years (104 patients) and those aged <90 years (212 patients). Regarding the National Comprehensive Cancer Network risk classification, there was no difference between groups. Univariate, multivariate, and Cox analyses of relapse-free survival of patients in both groups indicated that the recurrence risk was significantly high among those aged ≥90 years. Patients aged ≥90 years were at higher risk for recurrence, suggesting a need for closer follow-up than that for patients aged <90 years., (© 2024 Japanese Dermatological Association.)